Does Rallies show Form 4 insider transactions for OLMA?

Yes. Rallies tracks OLMA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is OLMA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for OLMA. It does not provide personalized investment advice.

OLMA (Olema Pharmaceuticals, Inc. Common Stock) Stock Analysis - Insider Trades

Olema Pharmaceuticals, Inc. Common Stock (OLMA) is a publicly traded Healthcare sector company. As of May 21, 2026, OLMA trades at $13.82 with a market cap of $1.13B and a P/E ratio of -7.24. OLMA moved +6.72% today. Year to date, OLMA is -44.38%; over the trailing twelve months it is +174.80%. Its 52-week range spans $2.86 to $36.26. Analyst consensus is strong buy with an average price target of $39.75. Rallies surfaces OLMA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading OLMA stock inside the company?

Recent OLMA insider activity includes Mitchell Shawnte sold 24.77K, Mitchell Shawnte sold 233, Mitchell Shawnte sold 15.00K, Harmon Cyrus sold 10.00K, and Kovacs Shane William Charles sold 100.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

OLMA Key Metrics

Key financial metrics for OLMA
Metric	Value
Price	$13.82
Market Cap	$1.13B
P/E Ratio	-7.24
EPS	$-1.87
Dividend Yield	0.00%
52-Week High	$36.26
52-Week Low	$2.86
Volume	21.13K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-162.45M
Gross Margin	0.00%

Recent OLMA Insider Trades

Mitchell Shawnte sold 24.77K (~$600.60K) on Mar 4, 2026.
Mitchell Shawnte sold 233 (~$5.75K) on Mar 4, 2026.
Mitchell Shawnte sold 15.00K (~$345.15K) on Mar 3, 2026.
Harmon Cyrus sold 10.00K (~$268.80K) on Jan 20, 2026.
Kovacs Shane William Charles sold 100.00K (~$2.87M) on Jan 15, 2026.

Latest OLMA News

Olema Oncology Ends Q1 with $505M Cash, $53M Loss; OPERA-01 Data Fall — May 12, 2026
Olema to Present Phase 1 OP-3136 Data and OPERA-02 Poster at ASCO — Apr 21, 2026
Olema Oncology reveals NCoR1-driven ER antagonism by palazestrant and OP-3136 synergy — Apr 17, 2026
Olema Oncology to Present Two Preclinical Posters on Palazestrant and OP-3136 — Mar 17, 2026
Olema Oncology Raises $218.5M and Advances Phase 3 Palazestrant Trials — Mar 16, 2026

OLMA Analyst Consensus

11 analysts cover OLMA: 0 strong buy, 10 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $39.75.

Common questions about OLMA

Who is trading OLMA stock inside the company?: Recent OLMA insider activity includes Mitchell Shawnte sold 24.77K, Mitchell Shawnte sold 233, Mitchell Shawnte sold 15.00K, Harmon Cyrus sold 10.00K, and Kovacs Shane William Charles sold 100.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for OLMA?: Yes. Rallies tracks OLMA insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is OLMA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for OLMA. It does not provide personalized investment advice.